Impact of the JUPITER trial on statin prescribing for primary prevention

Pharmacotherapy

Volumn 34, Issue 1, 2014, Pages 9-18

  Teng, Jennifer F T ^a   Gomes, Tara ^b,c   Camacho, Ximena ^b   Grundy, Scott ^d   Juurlink, David N ^b,c,e   Mamdani, Muhammad M ^b,c,f,g,h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Drug utilization; JUPITER trial; Primary prevention; Rosuvastatin; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME SERIES ANALYSIS;

DRUG UTILIZATION; JUPITER TRIAL; PRIMARY PREVENTION; ROSUVASTATIN; STATINS;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; ONTARIO; POPULATION SURVEILLANCE; PRIMARY PREVENTION; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84898037465     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1340     Document Type: Article

References (43)

1. Mitka M. Statin therapy in primary CVD prevention remains a hot-button topic for some. JAMA 2011;306: 2077-8.
2. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285: 2486-97.
3. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25: 567-79.
4. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359: 2195-207.
5. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001;161: 183-8.
6. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour? CMAJ 2001;164: 1695-6.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301-7.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: 1001-9.
10. Statistics Canada. Population by sex and age group, by province and territory. Statistics Canada. 2011. Available from http://www40.statcan.ca/101/ cst01/demo31a-eng.htm. Accessed February 3, 2012.
11. Ministry of Health and Long Term Care (Ontario). Drugs funded by Ontario Drug Benefit (ODB) Program E-formulary. 2011. Available from https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp. Accessed February 4, 2012.
12. Choudhry NK, Zagorski B, Avorn J, et al. Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis. Ann Pharmacother 2008;42: 1563-72.
13. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351: 543-51.
14. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305: 783-9.
15. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47: 1245-51.
16. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006;25: 2084-106.
17. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28: 3083-107.
18. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39: 33-8.
19. Yaffee R, McGee M. An introduction to time series analysis and forecasting: with applications of SAS® and SPSS. First. San Diego, CA: Academic Press; 2000.
20. Helfenstein U. Box-Jenkins modelling in medical research. Stat Methods Med Res 1996;5: 3-22.
21. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc 1979;74: 427-31.
22. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22: 913-27.
23. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA 2003;289: 3241-2.
24. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004;328: 1415-6.
25. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168: 553-7.
26. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375: 735-42.
27. Allery LA, Owen PA, Robling MR. Why general practitioners and consultants change their clinical practice: a critical incident study. BMJ 1997;314: 870-4.
28. Armstrong D, Reyburn H, Jones R. A study of general practitioners' reasons for changing their prescribing behaviour. BMJ 1996;312: 949-52.
29. Wyatt J. Use and sources of medical knowledge. Lancet 1991;338: 1368-73.
30. Gupta M, Singh N, Tsigoulis M, et al. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. Can J Cardiol 2012;28: 14-9.
31. Canadian Agency for Drugs and Technologies in Health. Comparative effectiveness of rosuvastatin versus other statins: a review of clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. Available from http://www.cadth.ca/media/pdf/htis/feb-2011/L0247- Rosuvastatin- final.pdf. Accessed May 19, 2013.
32. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297: 1344-53.
33. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360: 1395-407.
34. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295: 1556-65.
35. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372: 1231-9.
36. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357: 2248-61.
37. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother 2002;36: 1907-17.
38. DiNicolantonio J, Lavie C, Serebruany V, O'Keefe J. Statin wars: the heavyweight match - atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med 2013;125: 7-16.
39. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279: 1615-22.
40. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361: 1149-58.
41. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364: 685-96.
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: 7-22.
43. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368: 1155-63.